CRANBURY, N.J.--(BUSINESS WIRE)--July 25, 2006--Kos Pharmaceuticals, Inc. (Nasdaq:KOSP - News): Kos Pharmaceuticals, Inc. (Nasdaq:KOSP - News) today announced results from a study that demonstrates the benefits of combining aspirin with its new optimized Niaspan® (niacin extended-release tablets) Caplet Formulation (CF). This study was a single-dose, placebo-controlled three-way crossover, flush provocation study (N=156) evaluating the benefits of aspirin in combination with a maximum dose of optimized Niaspan CF for reducing the incidence, duration and severity of flushing, a relatively common, but transient effect for patients who take Niaspan to increase HDL-C, or “good” cholesterol.
